~ SAMe (S-Adenosyl-Methionine): A Natural Compound - References
References
1. Available at: http://www.ahrq.gov/clinic/epcsums/samesum.htm.Accessed October 21, 2004.
2. Available at: http://www.fdaadvisorycommittee.com/FDC/AdvisoryCommittee/Committees/Anti-Infective+Drugs/020204_Suicide/020204_SuicideR.htm. Accessed October 21, 2004.
3. Available at: http://www.breggin.com/31-49.pdf. Accessed October 21, 2004.
4. Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Feb;27(1):85-102.
5. Bourin M, David DJ, Jolliet P, Gardier A. Mechanism of action of antidepressants and therapeutic perspectives. Therapie. 2002 Jul- Aug;57(4):385-96.
6. Wilson K, Mottram P. A comparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: a meta-analysis. Int J Geriatr Psychiatry. 2004 Aug;19(8):754-62.
7. Degner D, Grohmann R, Kropp S, et al. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry. 2004 Mar;37 Suppl 1:S39-45.
8. Gregorian RS, Golden KA, Bahce A, Goodman C, Kwong WJ, Khan ZM. Antidepressant-induced sexual dysfunction. Ann Pharmacother. 2002 Oct;36(10):1577-89.
9. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002 Apr;63(4):357-66.
10. Rosen RC, Marin H. Prevalence of antide- pressant-associated erectile dysfunction. J Clin Psychiatry. 2003;64 Suppl 10:5-10.
11. Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther. 2003 Aug;25(8):2289-304.
12. No authors listed. Drugs vs. talk therapy: 3,079 readers rate their care for depression and anxiety. Consum Rep. 2004 Oct;69(10):22-9.
13. Nemeroff CB. Improving antidepressant adherence. J Clin Psychiatry. 2003;64 Suppl 18:25-30.
14. Delle Chiaie R, Pancheri P, Scapicchio P. Efficacy and tolerability of oral and intra-muscular S-adenosyl-L-methionine 1,4- butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. Am J Clin Nutr. 2002 Nov;76(5):1172S-6S.
15. Mischoulon D, Fava M. Role of S-adenosyl- L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr. 2002 Nov;76(5):1158S-61S.
16. Lieber CS, Packer L. S-Adenosylmethionine: molecular, biological, and clinical aspects— an introduction. Am J Clin Nutr. 2002 Nov;76(5):1148S-50S.
17. Bottiglieri T. S-Adenosyl-L-methionine (SAMe): from the bench to the bedside— molecular basis of a pleiotrophic molecule. Am J Clin Nutr. 2002 Nov;76(5):1151S-7S.
18. Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds EH. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry. 2000 Aug;69(2):228-32.
19. Brown R, Bottiglieri T, Colman C. Stop Depression Now: SAMe. New York, NY: Berkley Books; 1999.
20. McDowell I. Alzheimer's disease: insights from epidemiology. Aging (Milano). 2001 Jun;13(3):143-62.
21. Papakostas GI, Petersen T, Mischoulon D, et al. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy. J Clin Psychiatry. 2004 Aug;65(8):1096-8.
22. Tiemeier H, van Tuijl HR, Hofman A, Meijer J, Kiliaan AJ, Breteler MM. Vitamin B12, folate, and homocysteine in depression: the Rotterdam Study. Am J Psychiatry. 2002 Dec;159(12):2099-101.
23. Bressa GM. S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand Suppl. 1994;154:7-14.
24. Bell KM, Plon L, Bunney WE Jr, Potkin SG. S-adenosylmethionine treatment of depression: a controlled clinical trial. Am J Psychiatry. 1988 Sep;145(9):1110-4.
25. Janicak PG, Davis JM, Preskorn SH, Syd FJ Jr. Principles and Practices of Psychopharmacotherapy. Baltimore, MD: Williams and Wilkins; 1993.
26. Salmaggi P, Bressa GM, Nicchia G, Coniglio M, La Greca P, Le Grazie C. Double-blind, placebo-controlled study of S-adenosyl-L- methionine in depressed postmenopausal women. Psychother Psychosom. 1993;59(1):34-40.
27. Kagan BL, Sultzer DL, Rosenlicht N, Gerner RH. Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo- controlled trial. Am J Psychiatry. 1990 May;147(5):591-5.
28. Stafford RS, MacDonald EA, Finkelstein SN. National patterns of medication treatment for depression, 1987 to 2001. Primary Care Companion J Clin Psychiatry 2001;3(6):232-235.
29. Available at: http://www.clinicaltrials.gov/ct/show/NCT00070941?order=1. Accessed October 21, 2004.
30. Mato JM, Corrales FJ, Lu SC, Avila MA. S-Adenosylmethionine: a control switch that regulates liver function. FASEB J. 2002 Jan;16(1):15-26.
31. Martinez-Chantar ML, Garcia-Trevijano ER, Latasa MU, et al. Importance of a deficiency in S-adenosyl-L-methionine synthesis in the pathogenesis of liver injury. Am J Clin Nutr. 2002 Nov;76(5):1177S-82S.
32. Arteel G, Marsano L, Mendez C, Bentley F, McClain CJ. Advances in alcoholic liver disease. Best Pract Res Clin Gastroenterol. 2003 Aug;17(4):625-47.
33. Lieber CS. Liver diseases by alcohol and hepatitis C: early detection and new insights in pathogenesis lead to improved treatment. Am J Addict. 2001;10 Suppl:29-50.
34. Galan AI, Munoz ME, Palomero J, Moreno C, Jimenez R. Role of S-adenosylmethionine on the hepatobiliary homeostasis of glu- tathione during cyclosporine A treatment. J Physiol Biochem. 2000 Sep;56(3):189-200.
35. Loguercio C, Nardi G, Argenzio F, et al. Effect of S-adenosyl-L-methionine administration on red blood cell cysteine and glu- tathione levels in alcoholic patients with and without liver disease. Alcohol. 1994 Sep;29(5):597-604.
36. Lieber CS. S-adenosyl-L-methionine: its role in the treatment of liver disorders. Am J Clin Nutr. 2002 Nov;76(5):1183S-7S.
37. Lieber CS. S-Adenosyl-L-methionine and alcoholic liver disease in animal models: implications for early intervention in human beings. Alcohol. 2002 Jul;27(3):173-7.
38. Lieber CS. Alcoholic liver disease: new insights in pathogenesis lead to new treatments. J Hepatol. 2000;32(1 Suppl):113-28.
39. Tsai SM, Lee KT, Tsai LY. Effects of S- adenosyl-L-methionine on liver damage in experimental obstructive jaundice. Kaohsiung J Med Sci. 2001 Sep;17(9):455-60.
40. Purohit V, Russo D. Role of S-adenosyl-L- methionine in the treatment of alcoholic liver disease: introduction and summary of the symposium. Alcohol. 2002 Jul;27(3):151-4.
41. Ansorena E, Garcia-Trevijano ER, Martinez- Chantar ML, et al. S-adenosylmethionine and methylthioadenosine are antiapoptotic in cultured rat hepatocytes but proapoptotic in human hepatoma cells. Hepatology. 2002 Feb;35(2):274-80.
42. Pascale RM, Simile MM, De Miglio MR, Feo F. Chemoprevention of hepatocarcinogenesis: S-adenosyl-L-methionine. Alcohol. 2002 Jul;27(3):193-8.
43. McClain CJ, Hill DB, Song Z, et al. S- Adenosylmethionine, cytokines, and alcoholic liver disease. Alcohol. 2002 Jul;27(3):185-92.
44. Song Z, Joshi-Barve S, Barve S, McClain CJ. Advances in alcoholic liver disease. Curr Gastroenterol Rep. 2004 Feb;6(1):71-6.
45. Veal N, Hsieh CL, Xiong S, Mato JM, Lu S, Tsukamoto H. Inhibition of lipopolysaccharide-stimulated TNF-alpha promoter activity by S-adenosylmethionine and 5'-methylthioadenosine. Am J Physiol Gastrointest Liver Physiol. 2004 Aug;287(2):G352-62. Epub 2004 Apr 02.
46. Avila MA, Garcia-Trevijano ER, Lu SC, Corrales FJ, Mato JM. Methylthioadenosine. Int J Biochem Cell Biol. 2004 Nov;36(11):2125-30.
47. Hevia H, Varela-Rey M, Corrales FJ, et al. 5'-methylthioadenosine modulates the inflammatory response to endotoxin in mice and in rat hepatocytes. Hepatology. 2004 Apr;39(4):1088-98.
48. Yang H, Sadda MR, Li M, et al. S-adenosyl methionine and its metabolite induce apoptosis in HepG2 cells: Role of protein phos- phatase 1 and Bcl-x(S). Hepatology. 2004 Jul;40(1):221-31.
49. Ding C. Do NSAIDs affect the progression of osteoarthritis? Inflammation. 2002 Jun;26(3):139-42.
50. Gutierrez S, Palacios I, Sanchez-Pernaute O, et al. SAMe restores the changes in the proliferation and in the synthesis of fibronectin and proteoglycans induced by tumour necro- sis factor alpha on cultured rabbit synovial cells. Br J Rheumatol. 1997 Jan;36(1):27-31.
51. Barcelo HA, Wiemeyer JC, Sagasta CL, Macias M, Barreira JC. Effect of S-adenosylmethionine on experimental osteoarthritis in rabbits. Am J Med. 1987 Nov 20;83(5A):55-9.
52. Harmand MF, Vilamitjana J, Maloche E, Duphil R, Ducassou D. Effects of S-adenosylmethionine on human articular chondro- cyte differentiation. An in vitro study. Am J Med. 1987 Nov 20;83(5A):48-54.
53. Soeken KL, Lee WL, Bausell RB, Agelli M, Berman BM. Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis. J Fam Pract. 2002 May;51(5):425-30.
54. Lazzaroni M, Bianchi Porro G. Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations. Aliment Pharmacol Ther. 2004 Jul;20 Suppl 2:48-58.
55. Maccagno A, Di Giorgio EE, Caston OL, Sagasta CL. Double-blind controlled clinical trial of oral S-adenosylmethionine versus piroxicam in knee osteoarthritis. Am J Med. 1987 Nov 20;83(5A):72-7.
56. Caruso I, Pietrogrande V. Italian double- blind multicenter study comparing S-adeno-sylmethionine, naproxen, and placebo in the treatment of degenerative joint disease. Am J Med. 1987 Nov 20;83(5A):66-71.
57. Bradley JD, Flusser D, Katz BP, et al. A ran- domized, double blind, placebo controlled trial of intravenous loading with S-adenosyl- methionine (SAMe) followed by oral SAMe therapy in patients with knee osteoarthritis. J Rheumatol. 1994 May;21(5):905-11.
58. Konig B. A long-term (two years) clinical trial with S-adenosylmethionine for the treatment of osteoarthritis. Am J Med. 1987 Nov 20;83(5A):89-94.
59. Scott DL, Berry H, Capell H, et al. The long- term effects of non-steroidal anti-inflammatory drugs in osteoarthritis of the knee: a randomized placebo-controlled trial. Rheumatology (Oxford). 2000 Oct;39(10):1095-101.
60. Najm WI, Reinsch S, Hoehler F, Tobis JS, Harvey PW. S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. BMC Musculoskelet Disord. 2004 Feb 26;5(1):6.
1. Available at: http://www.ahrq.gov/clinic/epcsums/samesum.htm.Accessed October 21, 2004.
2. Available at: http://www.fdaadvisorycommittee.com/FDC/AdvisoryCommittee/Committees/Anti-Infective+Drugs/020204_Suicide/020204_SuicideR.htm. Accessed October 21, 2004.
3. Available at: http://www.breggin.com/31-49.pdf. Accessed October 21, 2004.
4. Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Feb;27(1):85-102.
5. Bourin M, David DJ, Jolliet P, Gardier A. Mechanism of action of antidepressants and therapeutic perspectives. Therapie. 2002 Jul- Aug;57(4):385-96.
6. Wilson K, Mottram P. A comparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: a meta-analysis. Int J Geriatr Psychiatry. 2004 Aug;19(8):754-62.
7. Degner D, Grohmann R, Kropp S, et al. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry. 2004 Mar;37 Suppl 1:S39-45.
8. Gregorian RS, Golden KA, Bahce A, Goodman C, Kwong WJ, Khan ZM. Antidepressant-induced sexual dysfunction. Ann Pharmacother. 2002 Oct;36(10):1577-89.
9. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002 Apr;63(4):357-66.
10. Rosen RC, Marin H. Prevalence of antide- pressant-associated erectile dysfunction. J Clin Psychiatry. 2003;64 Suppl 10:5-10.
11. Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther. 2003 Aug;25(8):2289-304.
12. No authors listed. Drugs vs. talk therapy: 3,079 readers rate their care for depression and anxiety. Consum Rep. 2004 Oct;69(10):22-9.
13. Nemeroff CB. Improving antidepressant adherence. J Clin Psychiatry. 2003;64 Suppl 18:25-30.
14. Delle Chiaie R, Pancheri P, Scapicchio P. Efficacy and tolerability of oral and intra-muscular S-adenosyl-L-methionine 1,4- butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. Am J Clin Nutr. 2002 Nov;76(5):1172S-6S.
15. Mischoulon D, Fava M. Role of S-adenosyl- L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr. 2002 Nov;76(5):1158S-61S.
16. Lieber CS, Packer L. S-Adenosylmethionine: molecular, biological, and clinical aspects— an introduction. Am J Clin Nutr. 2002 Nov;76(5):1148S-50S.
17. Bottiglieri T. S-Adenosyl-L-methionine (SAMe): from the bench to the bedside— molecular basis of a pleiotrophic molecule. Am J Clin Nutr. 2002 Nov;76(5):1151S-7S.
18. Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds EH. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry. 2000 Aug;69(2):228-32.
19. Brown R, Bottiglieri T, Colman C. Stop Depression Now: SAMe. New York, NY: Berkley Books; 1999.
20. McDowell I. Alzheimer's disease: insights from epidemiology. Aging (Milano). 2001 Jun;13(3):143-62.
21. Papakostas GI, Petersen T, Mischoulon D, et al. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy. J Clin Psychiatry. 2004 Aug;65(8):1096-8.
22. Tiemeier H, van Tuijl HR, Hofman A, Meijer J, Kiliaan AJ, Breteler MM. Vitamin B12, folate, and homocysteine in depression: the Rotterdam Study. Am J Psychiatry. 2002 Dec;159(12):2099-101.
23. Bressa GM. S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand Suppl. 1994;154:7-14.
24. Bell KM, Plon L, Bunney WE Jr, Potkin SG. S-adenosylmethionine treatment of depression: a controlled clinical trial. Am J Psychiatry. 1988 Sep;145(9):1110-4.
25. Janicak PG, Davis JM, Preskorn SH, Syd FJ Jr. Principles and Practices of Psychopharmacotherapy. Baltimore, MD: Williams and Wilkins; 1993.
26. Salmaggi P, Bressa GM, Nicchia G, Coniglio M, La Greca P, Le Grazie C. Double-blind, placebo-controlled study of S-adenosyl-L- methionine in depressed postmenopausal women. Psychother Psychosom. 1993;59(1):34-40.
27. Kagan BL, Sultzer DL, Rosenlicht N, Gerner RH. Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo- controlled trial. Am J Psychiatry. 1990 May;147(5):591-5.
28. Stafford RS, MacDonald EA, Finkelstein SN. National patterns of medication treatment for depression, 1987 to 2001. Primary Care Companion J Clin Psychiatry 2001;3(6):232-235.
29. Available at: http://www.clinicaltrials.gov/ct/show/NCT00070941?order=1. Accessed October 21, 2004.
30. Mato JM, Corrales FJ, Lu SC, Avila MA. S-Adenosylmethionine: a control switch that regulates liver function. FASEB J. 2002 Jan;16(1):15-26.
31. Martinez-Chantar ML, Garcia-Trevijano ER, Latasa MU, et al. Importance of a deficiency in S-adenosyl-L-methionine synthesis in the pathogenesis of liver injury. Am J Clin Nutr. 2002 Nov;76(5):1177S-82S.
32. Arteel G, Marsano L, Mendez C, Bentley F, McClain CJ. Advances in alcoholic liver disease. Best Pract Res Clin Gastroenterol. 2003 Aug;17(4):625-47.
33. Lieber CS. Liver diseases by alcohol and hepatitis C: early detection and new insights in pathogenesis lead to improved treatment. Am J Addict. 2001;10 Suppl:29-50.
34. Galan AI, Munoz ME, Palomero J, Moreno C, Jimenez R. Role of S-adenosylmethionine on the hepatobiliary homeostasis of glu- tathione during cyclosporine A treatment. J Physiol Biochem. 2000 Sep;56(3):189-200.
35. Loguercio C, Nardi G, Argenzio F, et al. Effect of S-adenosyl-L-methionine administration on red blood cell cysteine and glu- tathione levels in alcoholic patients with and without liver disease. Alcohol. 1994 Sep;29(5):597-604.
36. Lieber CS. S-adenosyl-L-methionine: its role in the treatment of liver disorders. Am J Clin Nutr. 2002 Nov;76(5):1183S-7S.
37. Lieber CS. S-Adenosyl-L-methionine and alcoholic liver disease in animal models: implications for early intervention in human beings. Alcohol. 2002 Jul;27(3):173-7.
38. Lieber CS. Alcoholic liver disease: new insights in pathogenesis lead to new treatments. J Hepatol. 2000;32(1 Suppl):113-28.
39. Tsai SM, Lee KT, Tsai LY. Effects of S- adenosyl-L-methionine on liver damage in experimental obstructive jaundice. Kaohsiung J Med Sci. 2001 Sep;17(9):455-60.
40. Purohit V, Russo D. Role of S-adenosyl-L- methionine in the treatment of alcoholic liver disease: introduction and summary of the symposium. Alcohol. 2002 Jul;27(3):151-4.
41. Ansorena E, Garcia-Trevijano ER, Martinez- Chantar ML, et al. S-adenosylmethionine and methylthioadenosine are antiapoptotic in cultured rat hepatocytes but proapoptotic in human hepatoma cells. Hepatology. 2002 Feb;35(2):274-80.
42. Pascale RM, Simile MM, De Miglio MR, Feo F. Chemoprevention of hepatocarcinogenesis: S-adenosyl-L-methionine. Alcohol. 2002 Jul;27(3):193-8.
43. McClain CJ, Hill DB, Song Z, et al. S- Adenosylmethionine, cytokines, and alcoholic liver disease. Alcohol. 2002 Jul;27(3):185-92.
44. Song Z, Joshi-Barve S, Barve S, McClain CJ. Advances in alcoholic liver disease. Curr Gastroenterol Rep. 2004 Feb;6(1):71-6.
45. Veal N, Hsieh CL, Xiong S, Mato JM, Lu S, Tsukamoto H. Inhibition of lipopolysaccharide-stimulated TNF-alpha promoter activity by S-adenosylmethionine and 5'-methylthioadenosine. Am J Physiol Gastrointest Liver Physiol. 2004 Aug;287(2):G352-62. Epub 2004 Apr 02.
46. Avila MA, Garcia-Trevijano ER, Lu SC, Corrales FJ, Mato JM. Methylthioadenosine. Int J Biochem Cell Biol. 2004 Nov;36(11):2125-30.
47. Hevia H, Varela-Rey M, Corrales FJ, et al. 5'-methylthioadenosine modulates the inflammatory response to endotoxin in mice and in rat hepatocytes. Hepatology. 2004 Apr;39(4):1088-98.
48. Yang H, Sadda MR, Li M, et al. S-adenosyl methionine and its metabolite induce apoptosis in HepG2 cells: Role of protein phos- phatase 1 and Bcl-x(S). Hepatology. 2004 Jul;40(1):221-31.
49. Ding C. Do NSAIDs affect the progression of osteoarthritis? Inflammation. 2002 Jun;26(3):139-42.
50. Gutierrez S, Palacios I, Sanchez-Pernaute O, et al. SAMe restores the changes in the proliferation and in the synthesis of fibronectin and proteoglycans induced by tumour necro- sis factor alpha on cultured rabbit synovial cells. Br J Rheumatol. 1997 Jan;36(1):27-31.
51. Barcelo HA, Wiemeyer JC, Sagasta CL, Macias M, Barreira JC. Effect of S-adenosylmethionine on experimental osteoarthritis in rabbits. Am J Med. 1987 Nov 20;83(5A):55-9.
52. Harmand MF, Vilamitjana J, Maloche E, Duphil R, Ducassou D. Effects of S-adenosylmethionine on human articular chondro- cyte differentiation. An in vitro study. Am J Med. 1987 Nov 20;83(5A):48-54.
53. Soeken KL, Lee WL, Bausell RB, Agelli M, Berman BM. Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis. J Fam Pract. 2002 May;51(5):425-30.
54. Lazzaroni M, Bianchi Porro G. Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations. Aliment Pharmacol Ther. 2004 Jul;20 Suppl 2:48-58.
55. Maccagno A, Di Giorgio EE, Caston OL, Sagasta CL. Double-blind controlled clinical trial of oral S-adenosylmethionine versus piroxicam in knee osteoarthritis. Am J Med. 1987 Nov 20;83(5A):72-7.
56. Caruso I, Pietrogrande V. Italian double- blind multicenter study comparing S-adeno-sylmethionine, naproxen, and placebo in the treatment of degenerative joint disease. Am J Med. 1987 Nov 20;83(5A):66-71.
57. Bradley JD, Flusser D, Katz BP, et al. A ran- domized, double blind, placebo controlled trial of intravenous loading with S-adenosyl- methionine (SAMe) followed by oral SAMe therapy in patients with knee osteoarthritis. J Rheumatol. 1994 May;21(5):905-11.
58. Konig B. A long-term (two years) clinical trial with S-adenosylmethionine for the treatment of osteoarthritis. Am J Med. 1987 Nov 20;83(5A):89-94.
59. Scott DL, Berry H, Capell H, et al. The long- term effects of non-steroidal anti-inflammatory drugs in osteoarthritis of the knee: a randomized placebo-controlled trial. Rheumatology (Oxford). 2000 Oct;39(10):1095-101.
60. Najm WI, Reinsch S, Hoehler F, Tobis JS, Harvey PW. S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. BMC Musculoskelet Disord. 2004 Feb 26;5(1):6.
Free Shipping in the Continental U.S. on Orders over $50
The statements made here have not been evaluated by the FDA. The foregoing statements are based upon sound and reliable studies, and are meant for informational purposes. Consult with your medical practitioner to determine the underlying cause of your symptoms. Please always check your purchase for possible allergins and correct dosage on the bottle before use.
While we work to ensure that product information is correct, on occasion manufacturers may alter their ingredient lists. Actual product packaging and materials may contain more and/or different information than that shown on our Web site. We recommend that you do not solely rely on the information presented and that you always read labels, warnings, and directions before using or consuming a product. For additional information about a product, please contact the manufacturer. Content on this site is for reference purposes and is not intended to substitute for advice given by a physician, pharmacist, or other licensed health-care professional. You should not use this information as self-diagnosis or for treating a health problem or disease. Contact your health-care provider immediately if you suspect that you have a medical problem. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease or health condition. Life Ex Online assumes no liability for inaccuracies or misstatements about products.
- Life Extension - Life Extension Vitamins
- Metabolism-Garcinia HCA Life Extension
- Glucose Management
- Longevity & Wellness
- Antioxidants
- Body Care
- Bones
- Brain
- Chinese / Mushrooms
- Digestion
- Energy / Sports
- Health Concerns
- Heart / Circulation
- Hormone / Prostate
- Immune
- Inflammatory Factors
- Intimacy
- Liver / Urinary
- Phyto Extracts
- Powdered Supplements
- Seasonal / Respiratory
- Vitamins / Multivitamins / Aminos / Minerals
- Life Extension CoQ10
